Dr. Edward Kai-Hua Chow, JALA Associate Editor/Asia and National University of Singapore, shares his SLAS2013 JALA and JBS Authors Workshop presentation. Learn more about these leading peer-reviewed journals, and then see Ed's tips for publication beginning on slide 16.
The document discusses two scientific journals - the Journal of Laboratory Automation (JALA) and the Journal of Biomolecular Screening (JBS). It provides information on their editors, impact factors, indexing in databases, scientific advisors and editorial boards. The goal of both journals is to publish research applying technological advances to scientific exploration and discovery of new therapeutics. Authors are encouraged to submit their work to these peer-reviewed, MEDLINE-indexed journals.
The document summarizes the results of a project that used a business intelligence software to identify potential drug discovery opportunities in oncology research related to cancer stem cells. The project searched literature databases to identify novel targets, compounds, and assays from research in the US and China since 2008. Key findings included several novel targets, compounds, and assays of interest to pharmaceutical companies, as well as identification of major researchers and institutions involved in related work in the US and China.
Toxicological testing for medical devices focuses on biocompatibility rather than pharmacology. Devices are a diverse category ranging from bandages to pacemakers. Testing assesses the safety of device materials and potential leachables through established biocompatibility standards rather than traditional toxicology studies for drugs. For most Class II and III devices, testing relies on a predicate device through the 510(k) process rather than full premarket approval and clinical trials. The goal is to evaluate biological hazards while ensuring reasonable safety based on prior human exposure to similar materials.
SMi Group's 7th annual Advances in Cell Based Assays conferenceDale Butler
This document summarizes a two-day conference on advances in cell-based assays being held on November 11-12, 2014 in London. The conference will explore the latest developments in cell-based assays and their application in drug discovery and development. Speakers will include representatives from pharmaceutical companies such as GSK, AstraZeneca, Novartis, UCB, and Merck Serono, as well as academics. Topics will include the use of cell-based assays in biologics drug discovery, challenges in validation and regulation, phenotypic screening, stem cell technologies, and 3D cell cultures. Workshops on leveraging cell-based assays for open innovation and evaluating cell-based assays in drug discovery will also be offered
This investor presentation summarizes Pressure BioSciences' business and technology. PBI develops and sells instruments and consumables for sample preparation using its patented Pressure Cycling Technology platform. Key points include that PBI has over 275 PCT systems installed, has accomplished revenue growth and debt reduction in recent years, and signed a marketing agreement with SCIEX to co-promote its PCT-SWATH technology for mass spectrometry applications. The presentation outlines PBI's technology applications, market opportunities, customer base, and near-term growth drivers including the SCIEX partnership and new product releases.
This document provides an overview of local biotech companies in Hong Kong Science and Technology Parks (HKSTP). It summarizes 15 diagnostic companies from local universities in HKSTP, including those from Chinese University (CUHK), University of Hong Kong (HKU), University of Science and Technology (UST), and Hong Kong Baptist University (HKBU). It highlights several local high-fliers, including Prof. Dennis Lo from CUHK who founded Arbele and Xcelom, and Prof. Michael Yang from CityU who founded Multigene Diagnostics and Genetel Pharmaceuticals. It also discusses trends in personalized medicine, obstacles, and examples of novel designs and a start-up biotech company to illustrate
Buffalo Biolabs (BBL) CRO capabilities, March 2014Sphere Software
Buffalo Biolabs (BBL) is a science-intensive Biotech company conducting preclinical contract research in a boutique fashion while solving intricate scientific problems, primarily in the field of cancer treatment, diagnostics and prevention; additional focus – infectious diseases.
The document discusses sources and types of contamination in complex biopharmaceutical processes. It outlines various factors that affect costs and success rates of batches. Specific causes of batch failures are explored, including contaminants from cell lines, media, water, plasticware, and personnel. Methods for preventing, detecting, and controlling contamination are presented, such as good aseptic technique, strategic use of antibiotics, and emerging technologies like rapid molecular testing.
The document discusses two scientific journals - the Journal of Laboratory Automation (JALA) and the Journal of Biomolecular Screening (JBS). It provides information on their editors, impact factors, indexing in databases, scientific advisors and editorial boards. The goal of both journals is to publish research applying technological advances to scientific exploration and discovery of new therapeutics. Authors are encouraged to submit their work to these peer-reviewed, MEDLINE-indexed journals.
The document summarizes the results of a project that used a business intelligence software to identify potential drug discovery opportunities in oncology research related to cancer stem cells. The project searched literature databases to identify novel targets, compounds, and assays from research in the US and China since 2008. Key findings included several novel targets, compounds, and assays of interest to pharmaceutical companies, as well as identification of major researchers and institutions involved in related work in the US and China.
Toxicological testing for medical devices focuses on biocompatibility rather than pharmacology. Devices are a diverse category ranging from bandages to pacemakers. Testing assesses the safety of device materials and potential leachables through established biocompatibility standards rather than traditional toxicology studies for drugs. For most Class II and III devices, testing relies on a predicate device through the 510(k) process rather than full premarket approval and clinical trials. The goal is to evaluate biological hazards while ensuring reasonable safety based on prior human exposure to similar materials.
SMi Group's 7th annual Advances in Cell Based Assays conferenceDale Butler
This document summarizes a two-day conference on advances in cell-based assays being held on November 11-12, 2014 in London. The conference will explore the latest developments in cell-based assays and their application in drug discovery and development. Speakers will include representatives from pharmaceutical companies such as GSK, AstraZeneca, Novartis, UCB, and Merck Serono, as well as academics. Topics will include the use of cell-based assays in biologics drug discovery, challenges in validation and regulation, phenotypic screening, stem cell technologies, and 3D cell cultures. Workshops on leveraging cell-based assays for open innovation and evaluating cell-based assays in drug discovery will also be offered
This investor presentation summarizes Pressure BioSciences' business and technology. PBI develops and sells instruments and consumables for sample preparation using its patented Pressure Cycling Technology platform. Key points include that PBI has over 275 PCT systems installed, has accomplished revenue growth and debt reduction in recent years, and signed a marketing agreement with SCIEX to co-promote its PCT-SWATH technology for mass spectrometry applications. The presentation outlines PBI's technology applications, market opportunities, customer base, and near-term growth drivers including the SCIEX partnership and new product releases.
This document provides an overview of local biotech companies in Hong Kong Science and Technology Parks (HKSTP). It summarizes 15 diagnostic companies from local universities in HKSTP, including those from Chinese University (CUHK), University of Hong Kong (HKU), University of Science and Technology (UST), and Hong Kong Baptist University (HKBU). It highlights several local high-fliers, including Prof. Dennis Lo from CUHK who founded Arbele and Xcelom, and Prof. Michael Yang from CityU who founded Multigene Diagnostics and Genetel Pharmaceuticals. It also discusses trends in personalized medicine, obstacles, and examples of novel designs and a start-up biotech company to illustrate
Buffalo Biolabs (BBL) CRO capabilities, March 2014Sphere Software
Buffalo Biolabs (BBL) is a science-intensive Biotech company conducting preclinical contract research in a boutique fashion while solving intricate scientific problems, primarily in the field of cancer treatment, diagnostics and prevention; additional focus – infectious diseases.
The document discusses sources and types of contamination in complex biopharmaceutical processes. It outlines various factors that affect costs and success rates of batches. Specific causes of batch failures are explored, including contaminants from cell lines, media, water, plasticware, and personnel. Methods for preventing, detecting, and controlling contamination are presented, such as good aseptic technique, strategic use of antibiotics, and emerging technologies like rapid molecular testing.
Virtual Drug Development in Southern California: A Pre-Clinical Focus -Presen...mwright1
BIOCOM CRO event May 2013: Being an early stage virtual company is no easy task. Managing resources and timelines while minimizing costs are the new normal for successful virtual companies. This two hour event and panel discussion hosted by Explora Biolabs and MPI Research will explore successful preclinical drug development in a virtual setting. Explora BioLabs will discuss selecting a drug candidate using early biology/efficacy models as well as best practices for screening and partnering with a CRO to streamline your candidate selection in a resource constrained environment. Building on that discussion, MPI Research will describe how to advance a compound from early GLP tox and safety testing into phase 1 while utilizing successful partnerships.
Joining the presenters for a follow-on panel discussion will be:
David Johnson, Director of DMPK, MicroConstants, Inc.
Richard Lin, CEO, Explora Biolabs
Greg Ruppert, Sr. Study Director and Director of Sales, MPI Research
Jennifer Spinella, Vice President, Regulatory Affairs & Quality Assurance, Rare Disease Therapeutics
Overcoming challenges in Drug DevelopmentCharles Oo
This document outlines strategies for overcoming challenges in drug development. It discusses the current long and expensive drug development process, as well as growing regulatory hurdles. It argues that innovation is needed, including open innovation models, a shift to personalized medicine, balancing drug toxicity and safety, leveraging technological advances like biomarkers, and using adaptive clinical trial designs. The key message is that new approaches are required to reduce costs, cycle times, and failure rates in drug development.
The document provides an overview of drug development and the biotechnology industry. It discusses the traditional and contemporary business models in the industry, which have shifted from closed innovation to more open innovation. It also outlines the services offered by one company, including clinical development support and regulatory consultancy. The document describes the company's research interests in areas like vaccines, proteins, and monoclonal antibodies. It includes organizational charts and provides details about the company's project pipeline across various phases of drug development. Finally, it discusses challenges in the industry like high costs and manufacturing techniques for cost reduction.
Patent awareness particularly in Bio-science related inventionsPankaj Kumar
The document discusses various topics related to life science patents and intellectual property rights (IPR) issues. It provides an overview of what constitutes a patent, patentable subject matter, and things that are not patentable. It also discusses various types of intellectual property, international bodies related to IPR, patent databases for prior art searches, components of a patent specification including claims, the patenting procedure, and considerations for drafting patent applications for biotechnological inventions and chemical patents.
Tacey E.K. White has over 25 years of experience in pharmaceutical safety assessment and drug development. She currently works as a senior consultant, advising on nonclinical safety strategies throughout drug development. Previously, she held roles at Exponent, Covance, and GlaxoSmithKline, where she designed and directed developmental and reproductive toxicity and juvenile toxicity studies to support regulatory submissions. She has deep expertise in areas like developmental toxicity, juvenile toxicity, and pregnancy and lactation labeling.
Challenges for drug development jsr slides aug 2013CincyTechUSA
This document discusses the challenges facing the pharmaceutical industry in drug development in the 21st century. It notes that R&D productivity has remained flat despite increased spending. Factors like the patent cliff, rising healthcare costs, and increased regulatory demands mean the industry can no longer rely on the blockbuster drug model. Innovation is now focused on targeted therapies for niche markets. Pharmacologists must guide drug development to demonstrate a new drug's safety, efficacy, and economic value in order to gain approval and reimbursement.
This document defines key terms related to biosafety and biosecurity risk assessment. It discusses the importance of risk assessment for effective resource allocation and regulatory compliance. Risk assessments should be performed initially and periodically, or when changes occur. They involve identifying hazards and risks, characterizing risks based on likelihood and consequences, determining if risks are acceptable, and implementing mitigation measures if needed. The processes for biosafety and biosecurity risk assessments are outlined, including defining the scenario or situation, risks, characterizing risks, acceptability determination, and risk mitigation implementation.
Cell based assays presentation V2_03_2012Pete Shuster
This document provides an executive overview of a company called Neuromics/Vitro Biopharma that develops pre-clinical tools for drug discovery using human stem cell-derived cell systems. The company offers physiologically relevant human cells and cellular systems to enable better in vitro screening and target identification, reducing animal models and shortening development timelines. Key offerings include human stem cell-derived neuronal cells, glial cells, immune cells and other cell types, specialized media, transfection reagents, markers and labeling technologies. The company aims to improve early drug discovery through more predictive human cell-based assays.
The document discusses the need for regulations to govern nanomedicine as it holds promise but also risks. It notes that while nanoparticles show potential in drug delivery, imaging and implants, regulatory frameworks have not fully addressed their oversight. It advocates that meticulous pre-clinical testing and expert review can help minimize risks until standards, definitions and safety protocols are in place to properly assess nanomaterials' interactions and impacts in biological systems.
The Open Source Drug Discovery (OSDD) strategy uses an open innovation model with a porous-walled funnel to facilitate the free flow of ideas and projects. It brings in more contributors to look at projects and enables redundancies and parallelization. OSDD acts as a facilitator to marry academic and delivery-focused approaches and provides expertise, discovery platforms, and coordination of activities from both individual and centrally coordinated projects. OSDD has established multiple platforms for drug discovery including compound management, screening, target validation, and mechanistic studies. It has an extensive portfolio involving over 180 principal investigators from over 100 institutions working on projects ranging from whole cell screening to structure-based drug design.
Major concerns exist for the large number of environmental chemicals which lack toxicity data. The tens of thousands of commercial substances in need of screening for potential human health effects would cost millions of dollars and take several decades to test in traditional animal-based guideline studies, and these concerns have led many researchers to increasingly rely on alternative screening methods. High-throughput testing (HTT) methods have been developed to evaluate the hazard potential of diverse chemical libraries and are helpful in prioritizing the compounds of greatest concern for adverse effects. As part of a multiagency project to identify substances for prioritized testing, the USEPA ’s National Center for Computational Toxicology (NCCT) ToxCast program has, to date, screened >3800 unique compounds for biological activity in some or all of over 800 assays. These efforts are designed to inform decision-makers of the bioactivity and/or toxicity of chemicals, but there remains a need to establish confidence in the applicability of these novel technologies to regulatory agencies. Here we describe the status of the NCCT’s development of descriptive ToxCast assay documentation designed to implement OECD Guidance Document No. 211 recommendations for describing non-guideline in vitro test methods to diverse audiences. These annotations are designed to offer a clear and comprehensive depiction of all aspects of the ToxCast and Tox21 assays - from the development of novel methods, to the technological relevancy for examinating chemical-target interactions, through the interpretation of the >1600 different analytical endpoints. Alterations and additions to the OECD Guidance template were necessary to a limited extent to accommodate existing data infrastructure supporting the ToxCast program. Integrating detailed context-based textual information with structured ontology-based annotations into a publicly available database will facilitate the evaluation of these assays for regulatory applications. Our current work will provide critical feedback useful in future improvements to the OECD reporting template. This work is concurrent with efforts to deposit ToxCast data into other publicly accessible repositories (e.g., PubChem BioAssay and DB-ALM) and will help fulfill NCCT’s commitment to increasing transparency and public accessibility to information produced by HTT studies conducted under the ToxCast program.
This abstract does not reflect USEPA policy.
Factors influencing researchers' skill development processBhaswat Chakraborty
This document discusses the skills development process for researchers in pharmaceutical R&D. It covers the various stages of drug discovery and development from lead compound identification to regulatory approval and marketing. It emphasizes that most pharmaceutical R&D scientists have postgraduate degrees in relevant fields. Adaptation for fresh graduates to their new roles can be challenging but mentoring helps. Key skills discussed include analytical thinking, teamwork, leadership, budget and project management, as well as communication and problem-solving abilities. Finding the right mentor is also highlighted as important for career guidance.
The document discusses the stages of clinical drug development, including preclinical testing, Phase I-III trials, and regulatory approval. Preclinical testing assesses safety in animals before human trials. Phase I trials primarily evaluate safety in small human groups. Phase II trials further assess safety and preliminary efficacy. Phase III trials are large-scale, placebo-controlled trials to prove efficacy and long-term safety for regulatory approval. The goal is to advance safely from preclinical to clinical testing and approval.
This document discusses the requirements and procedures for conducting in vitro studies according to Good Laboratory Practice (GLP). It outlines prerequisites like specialized infrastructure, training, and waste disposal arrangements. Prior requirements include justifying and characterizing the test system, and ensuring authenticity through identification, stability, functionality, and purity. Other responsibilities involve procedures for cryopreservation, maintaining sterility, and separating different studies and test systems. Proper documentation of all batch records, equipment maintenance, and cell origins must also be followed.
Chen I Wu has extensive experience in analytical chemistry. He received multiple degrees including a B.S. in Chemistry from Tunghai University and M.S. degrees in Analytical Chemistry from National Sun Yat-Sen University and the University of Kentucky. He currently works as an Analytical Chemist for the Office of Indiana State Chemist where he performs chemical analysis of environmental and industrial samples using techniques such as HPLC/MS/MS and GC/MS. Previously, he worked as a Technician and Research Assistant developing new methodologies for metabolic compound analysis using mass spectrometry.
The Department of Human Biology & Toxicology at UMONS provides expertise in predictive toxicology, metabonomics, QSAR approaches, and conventional toxicity studies in rodents to support risk assessment. It works with pharmaceutical, biomedical, food, and chemical companies, as well as academic labs. The department conducts applied research projects and offers services like toxicity profiling, biomarker identification, and training in predictive toxicology and risk assessment. It has specialized equipment for metabonomics studies in rodents and cell cultures.
This document provides an introduction to the edited book "Advances in Forensic Applications of Mass Spectrometry". The introduction summarizes that mass spectrometry techniques have become widely used in forensic analysis due to developments in analytical instrumentation. It overviews several applications of mass spectrometry covered in the book, including drug analysis, drug testing in hair, stable isotope analysis, fire debris analysis, and explosive residue analysis. The book aims to describe novel forensic applications enabled by advanced mass spectrometry instrumentation.
Can target-based drug discovery be reconciled with phenotypic assays in the context of drug repurposing? One of the questions discussed at the SLAS Drug Repurposing SIG meeting at SLAS2013.
The Allotrope Foundation led discussion on building an open framework for laboratory data - recommending a holistic approach to build upon & promote industry standards & best practices by providing software that instantiates them.
This file includes the SLAS2013 presentations of Paul A. Johnston of University of Pittsburgh; Douglas Auld of Novartis Institutes for Biomedical Research; and Lisa Minor of In Vitro Strategies, LLC.
The Screen Design and Assay Technology SIG meeting at SLAS2014, January 22 in San Diego, featured a presentation by Wayne J. Levin of Predictum titled Design of Experiment Challenges & Opportunities. The slides and supplementary material are provided here.
Virtual Drug Development in Southern California: A Pre-Clinical Focus -Presen...mwright1
BIOCOM CRO event May 2013: Being an early stage virtual company is no easy task. Managing resources and timelines while minimizing costs are the new normal for successful virtual companies. This two hour event and panel discussion hosted by Explora Biolabs and MPI Research will explore successful preclinical drug development in a virtual setting. Explora BioLabs will discuss selecting a drug candidate using early biology/efficacy models as well as best practices for screening and partnering with a CRO to streamline your candidate selection in a resource constrained environment. Building on that discussion, MPI Research will describe how to advance a compound from early GLP tox and safety testing into phase 1 while utilizing successful partnerships.
Joining the presenters for a follow-on panel discussion will be:
David Johnson, Director of DMPK, MicroConstants, Inc.
Richard Lin, CEO, Explora Biolabs
Greg Ruppert, Sr. Study Director and Director of Sales, MPI Research
Jennifer Spinella, Vice President, Regulatory Affairs & Quality Assurance, Rare Disease Therapeutics
Overcoming challenges in Drug DevelopmentCharles Oo
This document outlines strategies for overcoming challenges in drug development. It discusses the current long and expensive drug development process, as well as growing regulatory hurdles. It argues that innovation is needed, including open innovation models, a shift to personalized medicine, balancing drug toxicity and safety, leveraging technological advances like biomarkers, and using adaptive clinical trial designs. The key message is that new approaches are required to reduce costs, cycle times, and failure rates in drug development.
The document provides an overview of drug development and the biotechnology industry. It discusses the traditional and contemporary business models in the industry, which have shifted from closed innovation to more open innovation. It also outlines the services offered by one company, including clinical development support and regulatory consultancy. The document describes the company's research interests in areas like vaccines, proteins, and monoclonal antibodies. It includes organizational charts and provides details about the company's project pipeline across various phases of drug development. Finally, it discusses challenges in the industry like high costs and manufacturing techniques for cost reduction.
Patent awareness particularly in Bio-science related inventionsPankaj Kumar
The document discusses various topics related to life science patents and intellectual property rights (IPR) issues. It provides an overview of what constitutes a patent, patentable subject matter, and things that are not patentable. It also discusses various types of intellectual property, international bodies related to IPR, patent databases for prior art searches, components of a patent specification including claims, the patenting procedure, and considerations for drafting patent applications for biotechnological inventions and chemical patents.
Tacey E.K. White has over 25 years of experience in pharmaceutical safety assessment and drug development. She currently works as a senior consultant, advising on nonclinical safety strategies throughout drug development. Previously, she held roles at Exponent, Covance, and GlaxoSmithKline, where she designed and directed developmental and reproductive toxicity and juvenile toxicity studies to support regulatory submissions. She has deep expertise in areas like developmental toxicity, juvenile toxicity, and pregnancy and lactation labeling.
Challenges for drug development jsr slides aug 2013CincyTechUSA
This document discusses the challenges facing the pharmaceutical industry in drug development in the 21st century. It notes that R&D productivity has remained flat despite increased spending. Factors like the patent cliff, rising healthcare costs, and increased regulatory demands mean the industry can no longer rely on the blockbuster drug model. Innovation is now focused on targeted therapies for niche markets. Pharmacologists must guide drug development to demonstrate a new drug's safety, efficacy, and economic value in order to gain approval and reimbursement.
This document defines key terms related to biosafety and biosecurity risk assessment. It discusses the importance of risk assessment for effective resource allocation and regulatory compliance. Risk assessments should be performed initially and periodically, or when changes occur. They involve identifying hazards and risks, characterizing risks based on likelihood and consequences, determining if risks are acceptable, and implementing mitigation measures if needed. The processes for biosafety and biosecurity risk assessments are outlined, including defining the scenario or situation, risks, characterizing risks, acceptability determination, and risk mitigation implementation.
Cell based assays presentation V2_03_2012Pete Shuster
This document provides an executive overview of a company called Neuromics/Vitro Biopharma that develops pre-clinical tools for drug discovery using human stem cell-derived cell systems. The company offers physiologically relevant human cells and cellular systems to enable better in vitro screening and target identification, reducing animal models and shortening development timelines. Key offerings include human stem cell-derived neuronal cells, glial cells, immune cells and other cell types, specialized media, transfection reagents, markers and labeling technologies. The company aims to improve early drug discovery through more predictive human cell-based assays.
The document discusses the need for regulations to govern nanomedicine as it holds promise but also risks. It notes that while nanoparticles show potential in drug delivery, imaging and implants, regulatory frameworks have not fully addressed their oversight. It advocates that meticulous pre-clinical testing and expert review can help minimize risks until standards, definitions and safety protocols are in place to properly assess nanomaterials' interactions and impacts in biological systems.
The Open Source Drug Discovery (OSDD) strategy uses an open innovation model with a porous-walled funnel to facilitate the free flow of ideas and projects. It brings in more contributors to look at projects and enables redundancies and parallelization. OSDD acts as a facilitator to marry academic and delivery-focused approaches and provides expertise, discovery platforms, and coordination of activities from both individual and centrally coordinated projects. OSDD has established multiple platforms for drug discovery including compound management, screening, target validation, and mechanistic studies. It has an extensive portfolio involving over 180 principal investigators from over 100 institutions working on projects ranging from whole cell screening to structure-based drug design.
Major concerns exist for the large number of environmental chemicals which lack toxicity data. The tens of thousands of commercial substances in need of screening for potential human health effects would cost millions of dollars and take several decades to test in traditional animal-based guideline studies, and these concerns have led many researchers to increasingly rely on alternative screening methods. High-throughput testing (HTT) methods have been developed to evaluate the hazard potential of diverse chemical libraries and are helpful in prioritizing the compounds of greatest concern for adverse effects. As part of a multiagency project to identify substances for prioritized testing, the USEPA ’s National Center for Computational Toxicology (NCCT) ToxCast program has, to date, screened >3800 unique compounds for biological activity in some or all of over 800 assays. These efforts are designed to inform decision-makers of the bioactivity and/or toxicity of chemicals, but there remains a need to establish confidence in the applicability of these novel technologies to regulatory agencies. Here we describe the status of the NCCT’s development of descriptive ToxCast assay documentation designed to implement OECD Guidance Document No. 211 recommendations for describing non-guideline in vitro test methods to diverse audiences. These annotations are designed to offer a clear and comprehensive depiction of all aspects of the ToxCast and Tox21 assays - from the development of novel methods, to the technological relevancy for examinating chemical-target interactions, through the interpretation of the >1600 different analytical endpoints. Alterations and additions to the OECD Guidance template were necessary to a limited extent to accommodate existing data infrastructure supporting the ToxCast program. Integrating detailed context-based textual information with structured ontology-based annotations into a publicly available database will facilitate the evaluation of these assays for regulatory applications. Our current work will provide critical feedback useful in future improvements to the OECD reporting template. This work is concurrent with efforts to deposit ToxCast data into other publicly accessible repositories (e.g., PubChem BioAssay and DB-ALM) and will help fulfill NCCT’s commitment to increasing transparency and public accessibility to information produced by HTT studies conducted under the ToxCast program.
This abstract does not reflect USEPA policy.
Factors influencing researchers' skill development processBhaswat Chakraborty
This document discusses the skills development process for researchers in pharmaceutical R&D. It covers the various stages of drug discovery and development from lead compound identification to regulatory approval and marketing. It emphasizes that most pharmaceutical R&D scientists have postgraduate degrees in relevant fields. Adaptation for fresh graduates to their new roles can be challenging but mentoring helps. Key skills discussed include analytical thinking, teamwork, leadership, budget and project management, as well as communication and problem-solving abilities. Finding the right mentor is also highlighted as important for career guidance.
The document discusses the stages of clinical drug development, including preclinical testing, Phase I-III trials, and regulatory approval. Preclinical testing assesses safety in animals before human trials. Phase I trials primarily evaluate safety in small human groups. Phase II trials further assess safety and preliminary efficacy. Phase III trials are large-scale, placebo-controlled trials to prove efficacy and long-term safety for regulatory approval. The goal is to advance safely from preclinical to clinical testing and approval.
This document discusses the requirements and procedures for conducting in vitro studies according to Good Laboratory Practice (GLP). It outlines prerequisites like specialized infrastructure, training, and waste disposal arrangements. Prior requirements include justifying and characterizing the test system, and ensuring authenticity through identification, stability, functionality, and purity. Other responsibilities involve procedures for cryopreservation, maintaining sterility, and separating different studies and test systems. Proper documentation of all batch records, equipment maintenance, and cell origins must also be followed.
Chen I Wu has extensive experience in analytical chemistry. He received multiple degrees including a B.S. in Chemistry from Tunghai University and M.S. degrees in Analytical Chemistry from National Sun Yat-Sen University and the University of Kentucky. He currently works as an Analytical Chemist for the Office of Indiana State Chemist where he performs chemical analysis of environmental and industrial samples using techniques such as HPLC/MS/MS and GC/MS. Previously, he worked as a Technician and Research Assistant developing new methodologies for metabolic compound analysis using mass spectrometry.
The Department of Human Biology & Toxicology at UMONS provides expertise in predictive toxicology, metabonomics, QSAR approaches, and conventional toxicity studies in rodents to support risk assessment. It works with pharmaceutical, biomedical, food, and chemical companies, as well as academic labs. The department conducts applied research projects and offers services like toxicity profiling, biomarker identification, and training in predictive toxicology and risk assessment. It has specialized equipment for metabonomics studies in rodents and cell cultures.
This document provides an introduction to the edited book "Advances in Forensic Applications of Mass Spectrometry". The introduction summarizes that mass spectrometry techniques have become widely used in forensic analysis due to developments in analytical instrumentation. It overviews several applications of mass spectrometry covered in the book, including drug analysis, drug testing in hair, stable isotope analysis, fire debris analysis, and explosive residue analysis. The book aims to describe novel forensic applications enabled by advanced mass spectrometry instrumentation.
Can target-based drug discovery be reconciled with phenotypic assays in the context of drug repurposing? One of the questions discussed at the SLAS Drug Repurposing SIG meeting at SLAS2013.
The Allotrope Foundation led discussion on building an open framework for laboratory data - recommending a holistic approach to build upon & promote industry standards & best practices by providing software that instantiates them.
This file includes the SLAS2013 presentations of Paul A. Johnston of University of Pittsburgh; Douglas Auld of Novartis Institutes for Biomedical Research; and Lisa Minor of In Vitro Strategies, LLC.
The Screen Design and Assay Technology SIG meeting at SLAS2014, January 22 in San Diego, featured a presentation by Wayne J. Levin of Predictum titled Design of Experiment Challenges & Opportunities. The slides and supplementary material are provided here.
The document discusses service level agreements (SLAs) between companies and vendors. It provides the following key points:
- SLAs define expectations for performance, responsibilities, and metrics to measure the success of the vendor. They are an important legal agreement between the parties.
- SLAs should include metrics for assessing financial performance, responsiveness, technology utilization, processes, employee-related factors, customer satisfaction, and other deliverables.
- Properly utilized, SLAs help companies evaluate vendor performance, receive expected services, and manage changing expectations over time. However, SLAs are sometimes overlooked or underutilized.
Please join us as highly-rated APSCU convention speakers, Martha Lanaghen and Ann Cross share their experiences working with dozens of successful campuses around the country to bring you an idea-packed hour of solid strategies to increase your placement rates and ensure accuracy and compliance in your reporting.
You’ll learn:
• Five Innovative Ideas to Find Grads that are “missing” and get them re-engaged
• Easy-to-implement strategies for getting the whole campus involved in placing students
• The Five (sometimes forgotten) fundamentals of successful placement departments
• Tips and Tools for ensuring that your student files are accurate and reporting is compliant
• Two WOW concepts that change the placement roadmap instantly
The document describes different setup configurations for broadcasting video using LavaView, ranging from using a single internal or external webcam connected to a laptop, to more advanced setups using multiple external cameras connected to multiple laptops or advanced video and audio mixing equipment. It also covers options for screencasting and video casting using third-party software to broadcast the screen or existing video files.
JALA Editor-in-Chief Edward Kai-Hua Chow, Ph.D., of National University of Singapore shared step-by-step advice on how to design and write scientific research papers more clearly and effectively to improve their chances for successful publication at the recently held conference in Washington, DC. Learn what editors want, what they don't want and how reviewers evaluate manuscripts by reviewing slides from the session.
Experience Counts! Leveraging Internship/Externship Experience to Secure Employment for your Graduates.
Join highly-rated APSCU speaker Ann Cross of the Sparrow Group and Connie Johnson Ed.D, Chief Academic Officer at CTU for this interactive and engaging workshop about standardizing and implementing institutional wide externship best practices. This is not a theoretical workshop- You’ll hear stories of success, see data that supports employment outcomes and leave with tools that you can take back to your institution and use immediately.
CAPPS 2012 Presentation-Gainful Employment & the Externship ConnectionAnn Cross
•The externship isn’t just a student’s last course and job placement shouldn’t begin at graduation! An efficient and effective externship program is the dynamic connection which takes your students out of the classroom and into the workforce. Campus and education directors, compliance managers, placement directors and externship coordinators will all benefit from the comprehensive perspective of this diverse panel of industry experts and this lively presentation on leveraging technology to implement externship best practices in the era of gainful employment. The panel will address key issues effecting externship programs including: How to teach soft skills to hard students to minimize drops and increase employability; Overcoming paperwork – Streamlining your department’s processes can minimize administrative work, maximize compliance and get your staff out in the field working with students and sites; Effective site development – Employer engagement begins with your externship program; Hired upon graduation! Proven strategies to increase extern-to-hire conversion rates
Key Takeaway:
Colleges today face specific and unique challenges as they help their students out of the classroom and into the workforce. This session offers practical and strategic tools to help bridge the “Skills Gap” that students coming out of college face today as well as tools which help engage everyone’s participation in improving employment outcomes for your Graduates.
Description (paragraph form)
With an increased pressure on Institutions of Higher Learning to substantiate their course offerings with respect to employability; now more than ever, programs designed to specifically address soft-skills are the only viable way to prepare the student and close the “skills gap” that exists in the job market today.
More and more recent college graduates struggle to gain entry into their field due to what employers claim is a lack of hands on experience, professionalism and business acumen in students coming directly out of college.
Join highly-rated speaker Ann Cross for this interactive and engaging presentation about the benefits of incorporating soft-skills training through experiential learning into the student experience. For those who already have soft-skills training as part of your course offerings, this workshop will share some of the best practices from around the country.
The Sparrow Group has visited dozens of campuses in the last five years, and has seen what works, as well as the common mistakes and missed opportunities. This is not a theoretical workshop, but rather a workshop that focuses on practical, tactical programs that you can implement immediately. You’ll hear stories of success, see data that supports outcomes, and leave with tools that you can take back to the campus and use to improve employment outcomes.
Deploying Automated Workstreams and Computational Approaches for Generation of Toxicity Data Used for Hazard Identification, by Robert T. Dunn, II, Ph.D., DABT
The Sample Management SIG for 2014 will focus on (3) group discussions. These discussion topics were chosen based on the feedback from our SLAS2013 SIG. Each discussion topic will be an open forum to allow participants to contribute their ideas and personal insights. See the slides for more.
Este documento promociona varios procesadores de AMD, incluyendo los Phenom II, Athlon II y Sempron. Describe que los Phenom II ofrecen beneficios de múltiples núcleos con alto rendimiento y bajo consumo de energía. Los Athlon II también ofrecen múltiples núcleos, alta capacidad multitarea, gráficos avanzados y eficiencia energética. Los Athlon X2 duplican el rendimiento con dos núcleos. Finalmente, los Sempron ofrecen sólido rendimiento para aplicaciones
George Carlin reflete sobre como a sociedade moderna prioriza a velocidade, a tecnologia e o materialismo em detrimento das relações humanas significativas e do tempo de qualidade com os entes queridos. Ele argumenta que precisamos desacelerar, apreciar os pequenos momentos e expressar nosso amor uns pelos outros.
An Effective Security Mechanism for M-Commerce Applications Exploiting Ontolo...IJERA Editor
Health organizations are beginning to move mobile commerce services in recent years to enhance services and quality without spending much investment for IT infrastructure. Medical records are very sensitive and private to any individuals. Hence effective security mechanism is required. The challenges of our research work are to maintain privacy for the users and provide smart and secure environment for accessing the application. It is achieved with the help of personalization. Internet has provided the way for personalization. Personalization is a term which refers to the delivery of information that is relevant to individual or group of individuals in the format, layout specified and in time interval. In this paper we propose an Ontology Based Access Control (OBAC) Model that can address the permitted access control among the service providers and users. Personal Health Records sharing is highly expected by the users for the acceptance in mobile commerce applications in health care systems.
Décalogo derechos de autor y normas de incontecchecho2550
Este documento proporciona instrucciones sobre las mejores prácticas para usar normas ICONTEC y derechos de autor al redactar documentos. Detalla recomendaciones sobre el formato de papel, márgenes, fuente, portada, contenido, introducción y bibliografía. También explica la importancia de citar las fuentes de información para evitar el plagio y reconocer el trabajo de otros, ya sea citando textualmente o parafraseando.
O documento lista várias opções de publicidade no site TopCouples, incluindo banners, banners animados, banners expansíveis e backgrounds, com seus formatos, tamanhos máximos de arquivo, frequências e valores.
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Pbio Investor Presentation Global Online Growth Conference - Oct 2016RedChip Companies, Inc.
This investor presentation discusses Pressure BioSciences, Inc. (PBIO), a company that develops and sells instruments and consumables for biological sample preparation using pressure cycling technology (PCT). The presentation provides an overview of PBIO's business, leadership, financials, and growth opportunities. Key points include PBIO having over 275 PCT systems installed, generating $1.8 million in revenue in 2015, closing a $5 million investment to strengthen its balance sheet, and partnering with SCIEX, a leader in mass spectrometry, to co-market PCT sample preparation solutions. The presentation outlines PBIO's focus on the estimated multi-billion dollar markets for sample preparation and mass spectrometry and its goal to achieve
The document discusses searching the pharmacology literature. It outlines the five phases of the drug life cycle: drug discovery, pre-clinical research, clinical trials, review, and ongoing analysis. It provides examples of databases to search within each phase, such as PubMed, Embase, and ClinicalTrials.gov. Advanced search techniques are covered, including using subject headings, Boolean operators, and filters. It also reviews citation management software like RefWorks.
The document discusses the drug development process from discovery to approval. It covers key stages including discovery research, preclinical testing, clinical trials, regulatory review and approval, and product launch. Key aspects addressed are screening compounds for drug candidates, assessing safety and efficacy in animal and human studies, developing formulations, and engaging regulatory agencies for approval to market a new drug. The overall goal is to discover, develop and launch new pharmaceutical products that treat diseases and conditions.
This presentation provides an overview of Pressure BioSciences, Inc. Key points include:
- PBI develops instruments and consumables for pressure cycling technology (PCT) sample preparation. PCT uses repeated high-pressure cycles to control molecular interactions.
- PBI's primary market is the biopharma industry, where PCT systems are used from biomarker discovery through validation and quality control. Over 270 PCT systems have been installed.
- A new next-generation PCT instrument, the Barocycler 2320EXTREME, was recently released.
- PBI is also developing ultra-shear technology to produce nanoemulsions for applications in food, pharmaceuticals, and other
Lecture given to Unit 8 (INDS 208) -- Pathobiology Treatment and Prevention of Disease -- in the undergraduate medical curriculum at McGill University on September 10, 2012.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
NCTR is a research center within the FDA that conducts toxicology research to support risk assessment and regulatory decision making. It has unique facilities including primate and BSL-3 laboratories. NCTR research focuses on emerging issues like nanotechnology, nutrition, and critical path initiatives. Bioimaging technologies like microPET and MRI are used to study effects of substances like ketamine anesthesia on brain development in primates. Studies found ketamine increased neuronal cell death markers in the frontal cortex of developing monkeys.
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...Levi Shapiro
Presentation by Ryo Kosaka, Senior Research Scientist, Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST). Includes an overview of priority strategies in Life Sciences and Biotech and description of the organization of the Life Sciences and Biotech department. Recent projects include a Portable System for High-Speed DNA Quantification, Application of a cell microarray chip for clinical diagnosis and single cell analysis, Safe and Secure Artificial Heart, New diagnosis for liver fibrosis utilizing glycans, AIST ventures from the department of Life Science & Biotech as well as International cooperation.
Best Practices for Building an End-to-End Workflow for Microbial GenomicsJonathan Jacobs, PhD
Invited talk presented at 2019 CAFPA-ASM D.C. Branch
FALL MEETING on "Current Testing Approaches & Implications for Public Health" at the FDA in College Park, MD.
Quality for Biologics ' New ReportCritical quality attributes, process and change control, product variation, characterisation, and regulatory concernsSales of biologics grew by 20% in 2007, far faster than sales of small molecule drugs, which grew by not much more than 5%. The number of biologics being launched is also growing very rapidly, accounting for more than 25% of launches in 2007. But biologics are not like small molecules ' they are more complex to develop, test and produce. Any change in production may have a direct effect on both safety and efficacy. Making sure that development, testing and production is done correctly can be expensive, but getting it wrong can be even more expensive and may be disastrous for patients and for the companies involved.This unique 300 page report can help you to understand the processes involved ' knowledge that can save time and money and even make the difference between success and failure. The report covers all aspects of the subject including' Critical quality attributes ' Manufacturing process parameters' Process analytical technology' Physicochemical analysis,' Bioassays, ' Formulation and specifications' Product- and process-related impurities' Aggregation ' Non-clinical testing' Clinical development, ' Post-marketing period' Regulatory authority expectations' Risk management ' Comparability concernsQuality for Biologics is edited by Dr Nicole Lyscom and is written by senior industry experts from leading companies and organisations including:UCBUCB-CelltechEli LillyAmgenRocheParexel ConsultingGenentech
Pressure BioSciences is presenting their pressure cycling technology instruments and consumables. Their flagship product is the Barocycler 2320EXTREME instrument, which uses high pressure cycling to prepare biological samples for analysis. They have over 270 PCT systems installed worldwide and publications highlighting the advantages of PCT in biopharma sample preparation from discovery to clinical use. The company is poised for growth with their exclusive marketing agreement with SCIEX, expanded sales team, and focus on the multi-billion dollar biopharma market.
OMICS Publishing Group, Journal of Nanomedicine & Biotherapeutic Discovery (JNBD) is an international, peer-reviewed journal. Each issue of Journal of Nanomedicine & Biotherapeutic Discovery presents basic, clinical, and engineering research in the field of nanomedicine and the related biotherapeutic discovery. The regular features addresses the commercialization of nanomedicine advances, ethics in nanomedicine, funding opportunities, and other topics of interest to researchers and clinicians.
This document discusses innovation and pre-clinical development in Brazil. It outlines characteristics of innovative countries, recent advances in science and technology in Brazil, and the growth of post-graduate programs. It then discusses the importance of pre-clinical studies like toxicology, pharmacokinetics, safety pharmacology, and local tolerance to support clinical trials. Finally, it introduces the Centre of Innovation and Pre-Clinical Studies, which aims to conduct pre-clinical research, support pharmaceutical development, and contribute to generating national competence in drug innovation.
This document provides an overview of the November 2000 issue of JALA (Journal of Analytical Laboratories Automation). It describes the development of a novel robotic system for the New York Cancer Project biorepository in collaboration with the Medical Automation Research Center. The biorepository receives 50-100 blood samples per day which are processed robotically to extract, quantify, aliquot and store DNA, plasma and RNA to be accessible to investigators. The robotic system aims to provide rapid random access to the hundreds of thousands of DNA samples stored for high-throughput analysis in studies of gene-environment interactions and cancer risk.
The document summarizes NuLiv Science International's research focused on metabolism and the discovery of bioactive botanical fractions and compounds. It describes NuLiv's 6 interconnected business platforms, including focused research on metabolism, discovery of bioactive fractions/compounds, development of production processes, supplement products, sourcing/QC, and future wellness products. It provides details on NuLiv's research facilities, management team, scientific advisors, in vitro/in vivo/human research platforms, patents, and published papers. It also summarizes 6 bioactive fractions/compounds discovered and proprietary nutraceutical ingredients formulated with them.
This document provides guidelines for standardizing immunohistochemistry (IHC) testing in veterinary diagnostic laboratories. It addresses topics such as antibody selection, fixation, antigen retrieval, controls, buffers, and detection systems. The validation of an IHC test is important for both infectious diseases and neoplasms. Proper standardization and validation of IHC techniques will improve diagnostic accuracy in veterinary pathology. Following these guidelines will help obtain reproducible and consistent IHC results within and between laboratories.
Sandor Szalma (Janssen) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session of the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
Ontology-Driven Clinical Intelligence: A Path from the Biobank to Cross-Disea...Remedy Informatics
The discovery of clinical insights through effective management and reuse of data requires several conditions to be optimized: Data need to be digital, data need to be structured, and data need to be standardized in terms of metadata and ontology. This presentation describes a bioinformatics system that combines a next-generation biobank management model mapped to applicable international standards and guidelines with a master ontology that controls all input and output and is able to add unique properties to meet the specialized needs of clinicians for cross-disease research.
2011-10-11 Open PHACTS at BioIT World Europeopen_phacts
The document discusses the Innovative Medicines Initiative's Open PHACTS project, which aims to develop robust standards and apply them in a semantic integration platform ("Open Pharmacological Space") to integrate drug discovery data from various public and private sources. The project brings together partners from industry, academia, and non-profits to build an open infrastructure for linking drug discovery knowledge and supporting ongoing research. It outlines the technical approach, priorities, and initial progress on developing exemplar applications and a prototype "lash up" system.
Similar to How to Get Published in a Scientific Journal (20)
Adam Weinglass and Mary Jo Wildey from Merck & Co. share their winning presentation from SLAS2017 in Washington, DC. Join the conversation in the SLAS Screen Design and Assay Technology Special Interest Group LinkedIn group at https://www.linkedin.com/groups/3867725.
Timothy Dawes of Genentech and Elliot Hui of the University of California, Irvine share their well-received presentation from SLAS2017 in Washington, DC.
David A. Weil, Ph.D, senior applications scientist with Agilent Technologies, presented "Identification of Potential Bioactive Leachables and Extractables from Plastic Lab Ware by using GC and LC Separation Methods linked with MS Detection."
Dr. Praveen Balimane, senior staff fellow, Division of Clinical Pharmacology-1 at OCP/OTS/CDER/FDA, spoke during the Society for Laboratory Automation and Screening ADMET Special Interest Group Meeting on “Transporter Evaluation in Drug Development.”
Transporters, like CYPs, are being recognized as proteins that can play a pivotal role in dictating the ADME properties of drugs. A thorough understanding of potential roles of transporters in drug interactions and toxicity is important in drug development. The talk provided a high level overview of various transporter evaluation initiatives at the agency. Some of the topics discussed:
• On-going efforts on decision trees within the DDI guidance
• Novel emerging transporters impacting ADME
• Inter-play of hepatic transporters and liver-toxicity
• Inter-play of renal transporters and renal function
The ADMET SIG meeting at SLAS2014, January 21 in San Diego, featured a presentation by SIG Chair David M. Stresser, Ph.D., of Corning® GentestSM Contract Research Services. View his presentation, Time-Dependent Inhibition of Cytochrome P450: A Deep Dive Into Methods for Abbreviated Testing, here.
1. JALA & JBS Authors Workshop
How to Get Your Work Published
Dr.
Dr Edward Kai Hua Chow
Kai-Hua
Dept. of Pharmacology
Cancer Science Institute
National University of Singapore
3. Journal of Laboratory Automation (JALA)
Editor‐in‐Chief:
Dean Ho, Ph.D.
Professor
UCLA (2012 AY)
Impact Factor: 1.420 (Ranked 14 out of 32 in
Medical Laboratory Technology category
Scope: The Journal of Laboratory Automation
(JALA) is a multi‐disciplinary, bimonthly
international peer‐reviewed journal devoted to
international peer‐reviewed journal devoted to
the advancement of technology in the
laboratory.
JALA highlights innovation at the intersection of
academia, industry, and government research
and is backed by an internationally‐renowned
Scientific Advisory Board and Editorial Board.
Scientific Advisory Board and Editorial Board.
3
4. JALA Audience
JALA authors, readers, and reviewers are academic, commercial, and government
researchers, scientists, and engineers who conduct research and develop new
technologies to increase productivity, elevate data quality, reduce lab process
cycle times or enable experimentation that otherwise would be impossible
times, impossible.
4
5. JALA Indexing
Analytical Abstracts ProQuest
Biological Abstracts CSA Technology Research Database
BIOSIS Previews Science Citation Index Expanded (Web of
Ceramic Abstracts
Ceramic Abstracts Science)
Chemical Abstracts SciFinder
CINAHL SCIRUS
Compendex Scopus
Computer and Information Systems
Abstracts Journal
Corrosion Abstracts
EMBASE/Excerpta Medica
Engineering Index Monthly
Google Scholar
INSPEC
Journal Citation Report – Science edition
MEDLINE
5
6. JALA Scientific Advisors
World Leaders in Academic and Economic Innovation
Dr. Jing Cheng Dr. Nicolas Di Rooij Dr. Raymond Dessy Dr. Lee Hood
Capital Biochip EPFL Virginia Tech Institute for Systems
Tsinghua Univ. Inst Microtech Chemistry Biology
Dr. Edward McCabe Dr. Chad Mirkin Dr. Eiji Osawa Dr. Michael Phelps
Univ Colorado
U i C l d Northwestern Univ NanoCarbon Research M l/M d Ph
h i C b h Mol/Med Pharm
Linda Crnic Institute Chemistry Institute UCLA
6
7. JALA Editorial Board
Internationally‐Recognized Researchers and Business Leaders from 7 Countries
AuraSense Northwestern University
Automated Laboratory Processing Peking University
Biotic Laboratories Pennsylvania State University
Bristol-Myers
Bristol Myers Squibb PerkinElmer
BSSN Software Procter & Gamble
Chinese University of Hong Kong Syngenta Seeds
Genefluidics Technical University of Denmark
Harvard Medical School U.S. Dept. of Agriculture
Hospira Shanghai University of Arizona
Johns Hopkins University University of California, Irvine
Merck Research Laboratories University of California Los Angeles
California,
Nanyang Technological University University of Texas at Dallas
National University of Singapore University of Toronto
North Carolina State University University of Washington
Ziath
Zi th
7
8. JALA Editorial Highlights At‐A‐Glance
Editor s
Editor’s Choice Collections
•Diagnostics and Detection
•Emerging Technologies in Medicine
•Laboratory Automation and Robotics
•Microfluidics
Mi fl idi
•Nanomedicine
Special Issues
p
•Advancements in Biomedical Micro/Nano Tools & Technology (Jan. 25)
•New Developments in Global Health Technologies (Mar. 15)
•Novel Drug Development and Delivery
•Robotics for Laboratory Automation
•Next Generation Microarrays
•Nanomaterials and Microfluidics for Automation
•Nanomedicine
•Biosecurity and Biosafety
•Food and Agriculture
•Bionanotechnology
8
10. Journal of Biomolecular Screening (JBS)
Editor‐in‐Chief:
Robert Campbell, Ph.D.
Senior Research Advisor
Eli Lilly & Company
Impact Factor: 2.049
Ranked:
32 out of 73 in Chemistry, Analytical
79 out of 157 in Biotechnology & Applied
Microbiology
45 out of 72 in Biochemical Research Methods
10
11. Journal of Biomolecular Screening (JBS)
Scope: Readers are encouraged to submit material in any
relevant topic area, including: target
identification/validation, assay design and development,
assay technologies (novel applications, comparisons),
y g ( pp , p ),
automation/robotics, lead generation and/or lead
optimization, high‐content screening/imaging platforms,
virtual screening and chemoinformatics, data/image
analysis, statistics and information technologies/ methods,
sample management (e.g., library design, compound
logistics, chemical diversity), biological reagent production,
characterization and management for drug discovery (cell
lines, stem cells, surrogate tissues/species [e.g., xenopus,
zebrafish, yeast]), genomic and proteomic screening
zebrafish yeast]) genomic and proteomic screening
biomarkers, high‐throughput approaches to ADME/PK and
predictive toxicology, and legal/ licensing issues insofar as
they impact the field of screening and/or drug discovery.
The Journal will also publish reviews, mini reviews, and
The Journal will also publish reviews, mini‐reviews, and
perspectives in these topic areas. Other features include:
upcoming conferences and training seminars, product
applications, employment opportunities, society and
member news, and book reviews.
11
13. JBS Editorial Board
Internationally-Recognized Researchers and Business Leaders from 6 Countries
Albert-Ludwigs-Universitat Noscira
Freiburg Novartis Pharma
AstraZeneca Pfizer
Boehringer Ingelheim Promega
Pharmaceuticals Sanofi Aventis
Cellzome Tecan Italia
Eli Lilly & C
Company Threshold Pharmaceuticals
Exelixis U.S. Environmental Protection Agency
GlaxoSmithKline Venenum Biodesign
Johnson & Johnson Vertex Pharmaceuticals
Lankenau Institute for Medical
Research
Memorial Sloan-Kettering
Cancer C t
C Center
U.S. National Institutes of Health
13
14. JBS Editorial Highlights At‐A‐Glance
Editor’s Choice Collections
•ADME/Tox
•Assay Data Analysis, Statistics
y y
•Compound Management
•Epigenetics
•Flow Cytometry (FACS)-Based Screening Methods
•HCS, Imaging, Data Analysis
g g y
•High-Throughput Screening Methods
•High-Throughput Screening Reviews
•NMR, Mass Spectrometry-Based Screening Methods
Special Issues
•Data Mining and Analysis (TBD Soon)
•Phenotypic Drug Discovery (Jan. 25)
•Stem Cells in Drug Discovery
•Epigenetic-Targeted Drug Discovery
•High Content Screening, Imaging and Data Analysis
•Compound Management
14
16. How to Get Published
Central Message
Central Message
•What are the key take‐away points of your paper?
•Summarize the messages of your paper in 3‐5 sentences
Choosing the Right Journal
Choosing the Right Journal
•Choose the right audience
•Be realistic about the impact/significance of your paper
•IF versus the best audience/category
Manuscript Composition – Enhance the Readability
•Title
•Abstract
•Introduction
•Results
•Discussion
R f /Ci i
•References/Citing
16
17. Manuscript Composition
Title
•What is the most important message of your paper?
•The message is more than just the data
p g
•Capture the audience’s imagination
• Cellular‐Level Surgery Using Nano Robots (JALA, Dec 2012)
•Be Clear:
• Bad Example: Treatment of Pediatric Melanoma Patients with Lasers
• Better Example: Laser Treatment of Pediatric Melanoma Patients
•Follow journal rules for title length and format
17
18. Manuscript Composition
Abstract
•Establish the narrative of your paper
•Convince the editors, reviewers and audience to want to read your paper
g p p
•Should be able to stand on its own without reading the paper
•State the hypothesis, question or objective of the study
•Complete the story by answering the hypothesis, question or objective
•How does this work impact your field of research and the larger
scientific/medical/commercial industry?
i ifi / di l/ i li d ?
•Stay consistent with title and introduction in the use of keywords and concepts
•Follow the correct style and format
Follow the correct style and format
•Follow order of the manuscript (Intro‐Methods‐Results‐Discussion)
•Stay within the allowed word count
•Do not include data that isn’t in the paper
•Do not suggest conclusions that can’t be supported by the data in the paper
•Limit abbreviations to a minimum
•No references and no figure or table citations
18
19. Manuscript Composition
Introduction
•Why was this study conducted?
•Sufficiently introduce the current state of research without becoming a review paper
g y y
•Recognize key works that came before yours
•Be clear how your work differentiates from previous publications.
• What did you do differently?
• What is novel?
• Concisely reiterate/summarize the key talking points/data/ideas that you will
demonstrate in the paper and emphasized in abstract
Methods
Eff ti l d ib h t di f
•Effectively describe how studies were performed. d
•Explain techniques in sufficient detail that an expert in your field could effectively
replicate your work.
•Be clear about the source of materials
•Describe statistics techniques employed
•If your studies involved living subjects, describe ethical and regulatory considerations of
the study
19
20. Manuscript Composition
Results
•Order your Results and Figures in a clear and sensible manner that fits your narrative
•Provide enough data in Results to convince the audience of your conclusions
y
•Title your Results subsections in a concise and clear manner
•In each subsection, start by clearly stating why these experiments are important.
•State your results clearly and with no embellishments or overreaching conclusions
•Always begin and end with a bang (what are the most important experiments of the
paper?)?)
Discussion
•Explain why your work is important. This is your narrative. What conclusions do you
take from your Results that advance what is known in your field of research?
•Do not just summarize your results. Answer bigger questions.
•Do not be afraid to talk about the limitations of your work
Do not be afraid to talk about the limitations of your work
•How does your current work indicate where future research should go?
20
21. Originality
Importance of Citations
Importance of Citations
•Ideas are the currency of Academia
•Failure to cite violates the rights of the person who originated the idea
g gy
•Academics need to trace the genealogy of ideas
Originality of Research
•How does your work differentiate from work that came before it?
•What novel insights or conclusions can you make from your work?
Evaluation of Originality by Peer Reviewers
•How does your work compare to the work cited in your paper?
•How does your work compare to work that you failed to cite (This can kill your paper)
Description of Originality in Manuscript
•Create and maintain a narrative that easily explains why and how your work is novel.
•Differentiate your work from properly cited work that came before yours. Show how
your work extends beyond what is known.
21
22. The Importance of Citations
Ideas are the Currency of Academia
Ideas are the Currency of Academia
• Ideas enable the originator of the idea to receive credit for their work
• Citations are a key indicator of impact
• Giving credit to one who makes new discoveries is important for the field
Failing to Cite Violates the Rights of the Person who Originated the Idea
• It is important to keep track of sources
• During the course of describing new findings, it is important to formally describe
how prior discoveries have served as a foundation for new ideas
From: The Importance of Citation, Judy Hunter, Grinnell College
22
23. The Importance of Citations
Academics Need to Trace Genealogy of Ideas
Academics Need to Trace Genealogy of Ideas
• Inspiration for new ideas should be acknowledged
• Mapping out the course of innovation is important for those within the field as
those who are new to the field
h h h f ld
• Mapping out the course of innovation makes how your work is novel easier to
follow
From: The Importance of Citation, Judy Hunter, Grinnell College
23
24. The Importance of Citations – During Review Process
How are Citations Evaluated?
How are Citations Evaluated?
•Did the authors sufficiently acknowledge previous work?
•Do the citations sufficiently explain the genealogy of ideas leading up to this
paper?
Reviewer Response to Citations
•Thorough referencing will make the review process easier
•Failure to cite key papers that your work clearly builds on will greatly harm your
•Failure to cite key papers that your work clearly builds on will greatly harm your
paper and the reviewer’s perception of your work
Citations in Reviewers
Citations in Reviewers’ Critiques
•If citations are not sufficient in paper, Reviewers will point it out
•If Reviewers are not specific about requests for greater citation – Don’t just add 1
or 2 token cites.
24
25. Authorship Issues
Authorship Order
Authorship Order
• Which graduate student/postdoc/tech did the most work/led the project?
• Co‐first author is fine
• Lead PI should go last
• Gamesmanship: Do you have collaborators that helped with your project that
h h ll b h h l d h h
can add legitimacy to your work?
Corresponding Authorship
Corresponding Authorship
• The lead PI should generally be Corresponding Author. In cases of multi‐
disciplinary studies, can have two Corresponding Authors.
• Situation‐specific cases for making postdoctoral fellow Corresponding Author
Authorship Permissions
• Does everyone on the authorship list know they are associated with your
paper?
25
26. Peer Review Process
• The review process is confidential, and reviewers are obliged not to discuss papers or
p , g p p
authors with anyone outside of the SLAS editorial staff.
• Manuscripts are typically evaluated in response to stated Peer Review Guidelines
and initial feedback is usually provided to authors within four weeks after
and initial feedback is usually provided to authors within four weeks after
submission.
• Manuscripts can be accepted as written by reviewers, declined as inappropriate, or
as is more often the case, reviewers will suggest revisions in the SLAS Spirit of
i ft th i ill t ii i th SLAS S i it f
Mentorship.
• Authors are then offered the opportunity to revise and re‐submit their manuscripts,
or provide explanations in response to reviewer questions or suggestions.
• Revisions and responses are re‐reviewed by the editor‐in‐chief and/or peer
reviewers before final publishing decisions are made.
• Invited reviewers are asked to decline their invitation if they have any perceived
conflict of interest with the author, the author's affiliation and/or the topic of the
paper.
26
28. Content
1. Is the manuscript within the defined scope of the j
p p journal?
2. Is the subject of the paper of sufficient interest to the journal's readership?
3. Does the paper report a specific, identifiable, advance in knowledge?
p p p p , , g
4. Has the work reported in this paper been published before? (Suggestion: search
MEDLINE and/or Google Scholar by author and keywords.)
5. Are the title and abstract truly descriptive of the content?
6. Are the procedures and methods complete and sufficiently clear that the work
could be repeated by anyone knowledgeable in the field?
p y y g
7. Are the conclusions justified, sound and logically consistent?
8. Are the references to prior work p
p pertinent and complete?
p
28
29. Presentation
1. Is the paper as concise as it could be; consistent with clarity?
2. Are all figures and tables relevant and properly prepared?
3. Reviewers are not required t comment on grammar and punctuation.
3 R i t i d to t d t ti
Instead, reviewers are encouraged to suggest changes that would
remove ambiguity or clarify meaning.
29
30. Ethics
1. Papers under review are confidential and should not be discussed or shown to
p
others without the express permission of the editor-in-chief.
2. The identity of reviewers is kept anonymous. A reviewer should reveal his or her
identify to an author only with p
y y permission from the editor-in-chief.
30
31. General
1. Ensure the appropriate manuscript category is selected by the author. If y do not
pp p p g y y you
think the category selected by the author is the best fit for the manuscript,
recommend a more appropriate category.
2. Ensure the author is following the j
g journal's Instruction for Authors and American
Chemistry Society (ACS) Style Guidelines.
3. Assessments should be returned on or before the specified deadline. Reviewers
who may not be able to meet a deadline are urged to say so as soon as p
y g y possible.
4. Please keep in mind that reviewer manuscript evaluations and comments will be
relayed to authors as guides for revision. Be honest, but courteous. Offer
constructive criticism to the authors so they can benefit from your expertise.
y y p
Critique the manuscript, not the author.
5. Any comments for the editor's eyes only should be shared in a separate note.
31
32. Permission Guidelines
• Any text, tables, or figures reproduced from previously published work can only
Any text, tables, or figures reproduced from previously published work can only
be reprinted with written permission from the copyright holder.
• Permissions must be submitted with the manuscript, and must include print and
online publication.
li bli ti
• Acquiring permission is the sole responsibility of the author.
• The publication from which the material is taken must be listed in the
references.
32
33. Copyright and Simultaneous Submissions
• Manuscripts are considered for publication with the understanding that if a
Manuscripts are considered for publication with the understanding that if a
paper is accepted, copyright is transferred to the Society for Laboratory
Automation and Screening, and that no paper presenting the same information
has been or will be published elsewhere.
• If part of a contribution has appeared or will appear elsewhere, the author
must specify the details in the comments portion of his or her submission.
Simultaneous submissions of manuscripts to multiple journals at the same
p p j
time is not acceptable — please do not submit manuscripts that may be under
consideration by another publication or electronic medium.
• Published manuscripts may be published elsewhere only with the written
Published manuscripts may be published elsewhere only with the written
permission of SLAS.
• Authors whose research was funded by an NIH grant may submit the final,
accepted version of the manuscript for deposit in PubMedCentral. JALA requires
such authors to specify a release date of 11 months following the date of print
publication of the manuscript.
33
34. Ethics of Publishing
Definition of Plagiarism
Definition of Plagiarism
•From Merriam-Webster Dictionary: to steal and pass off (the ideas or
words of another) as one's own : use (another's production) without crediting
the source
Typical Responses to Plagiarism
•Author will be given an opportunity to explain themselves
•During review process – failure to be accepted
•During review process failure to be accepted
•After publication – Retraction
Conflict of Interests
Conflict of Interests
•All prospective authors must recognize and disclose any conflict of interest, or
potential conflict of interest, that may bias their work, or could be perceived to bias
their work, and acknowledge all financial support and any other personal
connections.
ti
•JALA follows the Uniform Requirements for Manuscripts of the International
Committee of Medical Journal Editors, especially as they relate to conflicts of
interest.
34